Adicet Bio, a pre-clinical stage biotechnology company, completed the merger with resTORbio, a clinical-stage biopharmaceutical company developing innovative medicines. Financial terms were not disclosed. “The closing of this merger transaction marks the beginning of a new chapter for Adicet as a publicly-traded company. We believe that our allogeneic gamma delta T cell approach may provide a unique treatment paradigm by combining the innate anti-tumour response, consistent with natural killer cells, and adaptive anti-tumour response consistent with other populations of T cells, such as alpha-beta T cells. We look forward to progressing multiple programs into the clinic, targeting both haematological and solid tumours," Chen Schor, Adicet President and Chief Executive Officer.